Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease—a randomised controlled trial
Abstract
To assess the efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease (SSc-ILD). This was a double-blind, randomised, placebo-controlled, pilot study. Subjects with SSc-ILD and forced vital capacity (FVC) between 50 and 80% of the predicted (%pred) value were randomised in 1:1 ratio to receive either pirfenidone (2400 mg/day) or placebo for 6 months. Primary outcome was the proportion of subjects with either...
Paper Details
Title
Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease—a randomised controlled trial
Published Date
Apr 1, 2020
Journal
Volume
40
Issue
5
Pages
703 - 710
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History